Market Overview

Albagaia announce Chris Hand as new Chairman of the Board

Share:

Executive team enhanced as the company continues its ambitious global
growth programme.

Albagaia Ltd, the leaders in rapid test technology for Legionella, today
announced the appointment of Dr Chris Hand as Chairman. Dr Hand has over
30 years' experience in the medical diagnostics industry. He co-founded
Abingdon Health Ltd, a leading company specialising in the development
and commercialisation of in vitro diagnostic products, rapid tests and
readers based on lateral flow technology. Chris served as a CEO of the
company for 7 years and has been Chairman of Abingdon Health since 2015.
He is also Chairman of Alta Bioscience Ltd, a specialist laboratory
business performing chemical synthesis of peptides and antibody
generation programmes.

Prior to this, Dr Hand co-founded Cozart Bioscience Ltd, the medical
diagnostics company and was Chief Executive of Cozart plc, following IPO
on AIM in 2004, until October 2007 when the company was sold to
Concateno plc for £65 million. Chris was a non-executive director of
Concateno plc until its sale to US-listed Alere Inc for £147m in August
2009, and was a non-executive director of Advanced Computer Software
plc, the AIM-listed leading software and IT services provider until the
sale to Vista Private Equity for £750m in March 2015.

Before co-founding Cozart, Chris was Director of Research for the
European base of DPC (part of Siemens Healthcare Solutions) developing a
wide range of immunodiagnostic kits in a variety of formats.

Greg Rankin, CEO of Albagaia said "This is the perfect time for Dr Hand
to join us to head up our Executive board. We are at a pivotal moment in
the history of the company as the market moves away from the traditional
lab culture method, which is slow and erratic, towards solutions that
provide actionable data in minutes. As suppliers of the world's fastest
water test for Legionella, we are poised to capitalise on this growth in
rapid testing, where our ongoing innovations will continue to provide
the information our partners need to deliver the level of protection
against Legionnaires' disease that today's market demands."

"We have begun an unprecedented programme of investment in the
Hydrosense brand which is set to create significant global growth for
the business. Dr Hand brings a vast depth of experience in increasing
company valuations, as well as fresh energy and ideas that will help the
business to make even more impact in our mission to help protect people
globally from the deadly threat of Legionnaires' disease."

About Albagaia

Albagaia is the leader in rapid testing technology for Legionella via
their Hydrosense brand. Hydrosense is the world's only test that can
detect Legionella on-site in 25 minutes (compared with 10-14 days for
traditional methods) and yet can be performed by anyone with minimal
training. It is used in water management, marine, offshore, healthcare
and other sectors to protect organisations' customers, employees and the
wider public from the growing threat of Legionnaires' disease.

View Comments and Join the Discussion!